DiaMedica Therapeutics Q2 2024 GAAP EPS $(0.13) Beats $(0.16) Estimate
Benzinga Newsdesk 2 years ago
EarningsEarnings BeatsNews
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent.
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent.